Cryoport (CYRX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for June 6, 2025, with virtual attendance available for shareholders.
Shareholders are encouraged to review proxy materials and vote by June 5, 2025.
Voting matters and shareholder proposals
Election of six directors is up for shareholder vote, with all nominees recommended by the board.
Ratification of Deloitte & Touche LLP as independent auditor for the fiscal year ending December 31, 2025.
Advisory vote on executive compensation for named executive officers.
Advisory vote on the preferred frequency of future say-on-pay votes, with “Year” recommended.
Other business may be transacted as properly brought before the meeting.
Board of directors and corporate governance
Six director nominees listed: Linda Baddour, Daniel Hancock, Robert Hariri, Ram M. Jagannath, Ramkumar Mandalam, and Jerrell W. Shelton.
Latest events from Cryoport
- Q3 2024 saw service growth, margin gains, and reaffirmed guidance despite product softness.CYRX
Q3 202414 Mar 2026 - Q2 2024 revenue hit $57.6M, with 51% cell/gene therapy growth and a $63.8M impairment loss.CYRX
Q2 202414 Mar 2026 - 2024 revenue hit $228.4M, Q4 margin rose to 45.8%, and 2025 guidance is $240–$250M with EBITDA positivity.CYRX
Q4 202414 Mar 2026 - Q1 2025 revenue up 10%; DHL deal and CRYOPDP sale to boost global reach and liquidity.CYRX
Q1 202514 Mar 2026 - FY2025 revenue rose 12% to $176.2M, with margin expansion and strong CGT market leadership.CYRX
Q4 20253 Mar 2026 - DHL acquires CRYOPDP for $195M, boosting growth, margins, and global reach in cell and gene therapy.CYRX
Investor Update26 Dec 2025 - Cost-cutting, innovation, and ESG focus drive growth as shareholders vote on key governance matters.CYRX
Proxy Filing2 Dec 2025 - Q2 2025 revenue up 14–14.5%, net income surged on CRYOPDP sale, guidance reaffirmed.CYRX
Q2 202523 Nov 2025 - Q3 revenue up 15.4% year-over-year, gross margin at 48.2%, guidance raised to $170–$174M.CYRX
Q3 202513 Nov 2025